A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL

Efgartigimod PH20 SC

Subcutaneous injection with efgartigimod PH20 SC

OTHER

Placebo PH20 SC

Subcutaneous injection with placebo PH20 SC

Trial Locations (200)

15222

Investigator Site 0010115, Pittsburgh

20007

Investigator Site 0010045, Washington D.C.

20122

Investigator site 0390014, Milan

33331

Investigator Site 0010104, Weston

40519

Investigator Site 0480013, Katowice

41013

Investigator site 0340013, Seville

42100

Investigator site 0390018, Reggio Emilia

43210

Investigator site 0010040, Columbus

45147

Investigator site 0490008, Essen

46804

Investigator Site 0010062, Fort Wayne

48202

Investigator Site 0010083, Detroit

52242

Investigator site 0010042, Iowa City

55455

Investigator Site 0010102, Minneapolis

60187

Investigator Site 0010079, Lisle

60612

Investigator site 0010112, Chicago

60637

Investigator site 0010193, Chicago

72758

Investigator Site 0010116, Springdale

73142

Investigator Site 0010095, Oklahoma City

90033

Investigator site 0010036, Los Angeles

Unknown

Investigator Site 0540001, Buenos Aires

Investigator Site 0540004, Buenos Aires

Investigator Site 0540003, Córdoba

Investigator Site 0610009, Adelaide

Investigator Site 0610004, Bedford Park

Investigator Site 0610002, Box Hill

Investigator Site 0610010, Clayton

Investigator Site 0610012, Garran

Investigator Site 0610001, Hobart

Investigator Site 0610011, Perth

Investigator Site 0610003, West Perth

Investigator Site 0610005, Westmead

Investigator Site 3590017, Plovdiv

Investigator Site 3590015, Sofia

Investigator Site 0560002, Santiago

Investigator Site 0560004, Temuco

Investigator Site 0560003, Viña del Mar

Investigator Site 0860003, Beijing

Investigator Site 0860013, Beijing

Investigator Site 0860008, Bengbu

Investigator Site 0860055, Huizhou

Investigator Site 0860009, Kunming

Investigator Site 0860012, Nanchang

Investigator Site 0860014, Shanxi

Investigator Site 0860015, Shenzhen

Investigator Site 0860001, Tianjin

Investigator Site 0860006, Wenzhou

Investigator Site 0860010, Wuhan

Investigator Site 0860002, Wuxi

Investigator Site 0860005, Zhejiang

Investigator Site 0860011, Zhengzhou

Investigator Site 0860058, Zhenjiang

Investigator site 0860062, Zhenjiang

Investigator Site 0450005, Roskilde

Investigator Site 0330009, Créteil

Investigator Site 0330018, Montpellier

Investigator Site 9950006, Tbilisi

Investigator Site 9950007, Tbilisi

Investigator Site 9950008, Tbilisi

Investigator Site 9950009, Tbilisi

Investigator Site 9950011, Tbilisi

Investigator Site 9950019, Tbilisi

Investigator Site 0490012, Giessen

Investigator Site 0300008, Athens

Investigator Site 0300010, Athens

Investigator Site 0300007, Pátrai

Investigator Site 0300009, Thessaloniki

Investigator Site 3530002, Dublin

Investigator Site 3530003, Dublin

Investigator Site 3530001, Galway

Investigator Site 9720013, Ashkelon

Investigator Site 9720010, Haifa

Investigator Site 9720012, Haifa

Investigator Site 9720008, Jerusalem

Investigator Site 9720011, Jerusalem

Investigator Site 9720007, Petah Tikva

Investigator Site 9720009, Tel Aviv

Investigator Site 0390037, Alessandria

Investigator Site 0390043, Ferrara

Investigator Site 0390045, Meldola

Investigator Site 0390032, Milan

Investigator Site 0390041, Napoli

Investigator Site 0390044, Napoli

Investigator Site 0390015, Novara

Investigator Site 0390035, Potenza

Investigator Site 0390011, Reggio Calabria

Investigator Site 0390046, Rome

Investigator Site 0390033, Terni

Investigator Site 0390036, Varese

Investigator Site 0810056, Chiba

Investigator Site 0810015, Hirakata

Investigator Site 0810010, Hiroshima

Investigator Site 0810053, Kanagawa

Investigator Site 0810051, Kitakyushu

Investigator Site 0810054, Kumamoto

Investigator Site 0810018, Maebashi

Investigator Site 0810057, Morioka

Investigator Site 0810012, Ōgaki

Investigator Site 0810017, Saitama

Investigator Site 0810016, Shibukawa

Investigator Site 0810023, Shimotsuke

Investigator Site 0810039, Shinagawa-Ku

Investigator Site 0810038, Tama

Investigator Site 0810052, Tokyo

Investigator Site 0810048, Tsukuba

Investigator Site 0810044, Yamanashi

Investigator Site 9620002, Amman

Investigator Site 9620001, Irbid

Investigator Site 0520002, Aguascalientes

Investigator Site 0520004, Chihuahua City

Investigator Site 0520007, México

Investigator Site 0520003, Monterrey

Investigator Site 0520001, Oaxaca City

Investigator Site 0640001, Auckland

Investigator Site 0640005, Christchurch

Investigator Site 0640002, Palmerston North

Investigator Site 0470002, Bergen

Investigator Site 0470003, Oslo

Investigator Site 0480014, Lublin

Investigator Site 0480026, Nowy Sącz

Investigator Site 0480037, Skorzewo

Investigator Site 0480039, Torun

Investigator Site 0480033, Warsaw

Investigator Site 3510006, Braga

Investigator Site 3510003, Coimbra

Investigator Site 3510002, Lisbon

Investigator Site 3510005, Lisbon

Investigator Site 3510007, Lisbon

Investigator Site 3510001, Porto

Investigator Site 3510004, Porto

Investigator Site 0400005, Bucharest

Investigator Site 0400006, Bucharest

Investigator Site 0400009, Bucharest

Investigator Site 0400012, Bucharest

Investigator Site 0400016, Cluj-Napoca

Investigator Site 0400007, Craiova

Investigator Site 0400011, Sibiu

Investigator Site 0400008, Târgu Mureş

Investigator Site 0070006, Kaluga

Investigator Site 0070040, Kirov

Investigator Site 0070026, Moscow

Investigator Site 0070038, Nizhny Novgorod

Investigator Site 0070037, Novosibirsk

Investigator Site 0070024, Pyatigorsk

Investigator Site 0070025, Saint Petersburg

Investigator Site 0070039, Smolensk

Investigator Site 0070015, Syktyvkar

Investigator Site 0070012, Tula

Investigator Site 3810006, Belgrade

Investigator Site 3810008, Kragujevac

Investigator Site 0270005, George

Investigator Site 0270003, Johannesburg

Investigator Site 0270004, Observatory

Investigator Site 0270001, Pretoria

Investigator Site 0270002, Randburg

Investigator Site 0820005, Seongnam

Investigator Site 0820003, Seoul

Investigator Site 0820004, Seoul

Investigator Site 0820006, Seoul

Investigator Site 0820007, Seoul

Investigator Site 0820008, Seoul

Investigator Site 0340024, Alava

Investigator Site 0340006, Barcelona

Investigator Site 0340023, Barcelona

Investigator Site 0340037, Madrid

Investigator Site 0340022, Murcia

Investigator Site 0340036, Sabadell

Investigator Site 0340004, Valencia

Investigator Site 8860001, New Taipei City

Investigator Site 8860003, Taoyuan District

Investigator Site 0660002, Bangkok

Investigator Site 0660003, Bangkok

Investigator Site 0660005, Bangkok

Investigator Site 0660008, Bangkok

Investigator Site 0660001, Bangkok Noi

Investigator Site 0660004, Chiang Mai

Investigator Site 0660009, Khon Kaen

Investigator Site 0660006, Pathum Thani

Investigator Site 2160006, Sfax

Investigator Site 2160001, Sousse

Investigator Site 2160002, Tunis

Investigator Site 0900007, Adapazarı

Investigator Site 0900003, Ankara

Investigator Site 0900006, Ankara

Investigator Site 0900008, Ankara

Investigator Site 0900015, Ankara

Investigator Site 0900016, Edirne

Investigator Site 0900013, Istanbul

Investigator Site 0900004, Izmir

Investigator Site 0900014, Kocaeli

Investigator Site 0900018, Malatya

Investigator Site 0900010, Mersin

Investigator Site 0900009, Samsun

Investigator Site 0900017, Tekirdağ

Investigator Site 0900019, Trabzon

Investigator Site 0440005, Coventry

Investigator Site 0440008, London

Investigator Site 0440041, London

Investigator Site 0440014, Truro

08035

Investigator Site 0340007, Barcelona

BD9 6RJ

Investigator site 0440011, Bradford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY

NCT04687072 - A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter